PR89727

AUSTIN, Texas, May 26, 2021 /PRNewswire=KYODO JBN/ --

The leader of the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's

Medical Center ( https://tcainstitute.com/ ) participated in a clinical study

to evaluate the safety and effectiveness of a new lattice sphere catheter

designed to optimize procedural efficiency and efficacy across a broad range of

cardiac arrhythmias. Andrea Natale, M.D., F.H.R.S., F.A.C.C., F.E.S.C., cardiac

electrophysiologist and executive medical director of TCAI, recently

participated in the first-in-human trials of this catheter in Europe.

"This new transformative technology enables a faster and more precise process

for how we deliver energy during complex ablation procedures," Dr. Natale said.

"The treatment provides a safer option for patients, as it may prevent

collateral damage to surrounding tissue to ensure the best possible outcomes."

The new expandable, cardiac-specific catheter is used to deliver focal pulsed

field ablation (PFA) and/or radiofrequency ablation (RFA). PFA delivers pulsed

electric field, a non-thermal energy modality, to ablate cardiac tissue through

a process known as irreversible electroporation (IRE), while RFA ablates tissue

thermally using radiofrequency.

The ablation catheter has an expandable lattice sphere at its tip, which allows

physicians to create high-resolution maps and deliver a controlled and tailored

ablation procedure using PFA or RFA. Additionally, the mapping system is

integrated with the device and enables the rapid creation of detailed

electroanatomical maps, providing increased accuracy and improving patient

outcomes.

This technology is expected to be available to patients at TCAI next year.

Media Contact:

Stacy Slayden

Elizabeth Christian Public Relations

SSlayden@EChristianPR.com

+1 254.592.2767 cell

SOURCE  Texas Cardiac Arrhythmia Institute at St. David’s Medical Center